September 25, 2016 4:36 AM ET

Biotechnology

Company Overview of Cytos Biotechnology AG

Company Overview

As of January 20, 2016, Cytos Biotechnology AG was acquired by Kuros Biosurgery AG, in a reverse merger transaction. Cytos Biotechnology AG focuses on the development and commercialization of biopharmaceutical products for use in the treatment and prevention of chronic diseases. The company has collaborative research, option, and license agreement with Novartis for the development of CAD106, an active immunotherapy for the treatment of patients with Alzheimer’s disease; license agreement with Pfizer Inc. for developing an anti-IgE vaccine; and collaborative research, development, and commercialization agreement with Singapore’s Agency for Science, Technology and Research. Cytos Biotechnology...

Wagistrasse 25

Schlieren,  8952

Switzerland

Phone:

41 44 733 47 47

Fax:

41 44 733 47 40

Key Executives for Cytos Biotechnology AG

Cytos Biotechnology AG does not have any Key Executives recorded.

Cytos Biotechnology AG Key Developments

Cytos Biotechnology AG has Changed its Ticker to KURN from CYTN

Effective January 20, 2016, Cytos Biotechnology AG changed its SIX Swiss Exchange stock ticker symbol to KURN from CYTN.

Cytos Biotechnology Ltd. Announces Management Changes

Cytos Biotechnology Ltd. announced that the board of directors has constituted itself with Dr. Christian Itin stepping down as CEO but remaining as chairman of the board and Mr. Dominik Ellenrieder being appointed as the vice chairman of the board. Further, the newly constituted board elected Didier Cowling as chief executive officer, Dr. Alistair Irvine as chief business officer, Dr. Jason Schense as chief technology officer and confirmed Harry Welten as the chief financial officer. All appointments are effective upon closing of the acquisition of Kuros Biosurgery Holding AG which is expected to take place within the next few weeks.

Cytos Biotechnology AG, Special/Extraordinary Shareholders Meeting, Jan 06, 2016

Cytos Biotechnology AG, Special/Extraordinary Shareholders Meeting, Jan 06, 2016, at 10:30 Central European Standard Time. Agenda: To approve the transaction with Kuros Biosurgery Holding AG.

Similar Private Companies By Industry

Company Name Region
AB2 Bio Ltd. Europe
ADC Therapeutics SA Europe
AlloCyte Pharmaceuticals AG Europe
Amal Therapeutics SA Europe
AmVac AG Europe

Recent Private Companies Transactions

Type
Date
Target
Merger/Acquisition
December 3, 2015
--
 

The information and data displayed in this profile are created and managed by Capital IQ, a Standard & Poor's company. Bloomberg.com does not create or control the content. For inquiries, please contact Capital IQ directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
The Advertising Council, Inc. United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Cytos Biotechnology AG, please visit www.cytos.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.